Octreotide: Difference between revisions
Ostermayer (talk | contribs) |
Ostermayer (talk | contribs) |
||
| Line 41: | Line 41: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits | A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits Growth Gormone, Gastrin, Vasoactive intestinal peptide (VIP), Gastrin, Serotonin, and decreases Insulin like growth factor-1 (IGF-1), serotonin and it decreases splanchnic blood flow. | ||
==Comments== | ==Comments== | ||
*Although used in the ED mainly for sulfonylurea overdose and vatical bleeding, it is used in outpatient and inpatient medicine for the treatment of acromegaly, carcinoid tumors, and VIPomas | *Although used in the ED mainly for sulfonylurea overdose and vatical bleeding, it is used in outpatient and inpatient medicine for the treatment of acromegaly, carcinoid tumors, and VIPomas | ||
Revision as of 21:13, 11 May 2016
Administration
- Type: Octapeptide
- Dosage Forms:
- Routes of Administration: IV, IM, or SQ
- Common Trade Names: Sandostatin, Sandostatin LAR
Adult Dosing
Variceal Bleeding
- Initial Bolus: 50mcg IV (range 25-100mcg)
- Drip rate: 25-50 mcg/hr IV
Sulfonylurea Overdose
- 50-75 mpg SQ or IM every 6 hrs as needed
Pediatric Dosing
Sulfonylurea Overdose
- 1-2 mpg/kg SQ or IM
Special Populations
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
A peptide that mimics endogenous somatostatin. Somatostatin is released by the pancreas, pyloric antrum, and duodenum and inhibits Growth Gormone, Gastrin, Vasoactive intestinal peptide (VIP), Gastrin, Serotonin, and decreases Insulin like growth factor-1 (IGF-1), serotonin and it decreases splanchnic blood flow.
Comments
- Although used in the ED mainly for sulfonylurea overdose and vatical bleeding, it is used in outpatient and inpatient medicine for the treatment of acromegaly, carcinoid tumors, and VIPomas
- Octreotide was originally used as a opiod antagonist and is still used off label as a second/third line therapy for diarrhea from opiod withdrawal because of antidiarrheal properties.[1]
See Also
References
- ↑ Carreno JE et al. 24-hour opiate detoxification and antagonist induction at home– the ‘asturian method’: A report on 1368 procedures. Addict Biol. 2002;7(2):243-250.